SLC1A2 and Anxiety: Inhibition of GLT-1 by local treatment of the GLT-1 inhibitor generates depressive- and anxiety-like behaviors, as indicated by the results of the intracranial self-stimulation and the elevated plus maze and fear conditioning tests.